Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease

Jie, Caitlin V M L; Treyer, Valérie; Schibli, Roger; Mu, Linjing

doi:10.3390/ph14020110

Cited by 71 publications

(78 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, most of these radiotracers encountered some major limitations and have not been fully validated yet. Tauvid ([ 18 F]-Flortaucipir) was approved by the U.S. Food and Drug Administration (FDA) in 2020 for PET imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer′s disease (AD) based on Tau pathology [ 76 ].…”

Section: Tau Pet Imagingmentioning

confidence: 99%

“…The target of [ 18 F]T808 (similarly to [ 18 F]T807) is aggregates of hyperphosphorylated Tau (PHF). Although [ 18 F]T808 showed favorable kinetic properties, this agent encountered some limitations due to the high bone uptake, which revealed the problem of defluorination [ 76 , 86 ].…”

Section: Tau Pet Imagingmentioning

confidence: 99%

“…Tauvid is an [ 18 F] labeled benzimidazole pyridine derivative, selected and developed by screening a varied chemical class of compounds using isolated PHF-Tau from postmortem AD brain tissues and intact human brain tissue sections [ 92 ]. Tauvid is also known as [ 18 F]Flortaucipir, [ 18 F]AV-1451 and [ 18 F]T807 [ 76 ].…”

Section: Tau Pet Imagingmentioning

confidence: 99%

See 2 more Smart Citations

Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective

Ricci

Cimini

Camedda

et al. 2021

IJMS

View full text Add to dashboard Cite

Abnormal accumulation of Tau protein is closely associated with neurodegeneration and cognitive impairment and it is a biomarker of neurodegeneration in the dementia field, especially in Alzheimer’s disease (AD); therefore, it is crucial to be able to assess the Tau deposits in vivo. Beyond the fluid biomarkers of tauopathy described in this review in relationship with the brain glucose metabolic patterns, this review aims to focus on tauopathy assessment by using Tau PET imaging. In recent years, several first-generation Tau PET tracers have been developed and applied in the dementia field. Common limitations of first-generation tracers include off-target binding and subcortical white-matter uptake; therefore, several institutions are working on developing second-generation Tau tracers. The increasing knowledge about the distribution of first- and second-generation Tau PET tracers in the brain may support physicians with Tau PET data interpretation, both in the research and in the clinical field, but an updated description of differences in distribution patterns among different Tau tracers, and in different clinical conditions, has not been reported yet. We provide an overview of first- and second-generation tracers used in ongoing clinical trials, also describing the differences and the properties of novel tracers, with a special focus on the distribution patterns of different Tau tracers. We also describe the distribution patterns of Tau tracers in AD, in atypical AD, and further neurodegenerative diseases in the dementia field.

show abstract

Section: Tau Pet Imagingmentioning

confidence: 99%

Section: Tau Pet Imagingmentioning

confidence: 99%

See 1 more Smart Citation

Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective

Ricci

Cimini

Camedda

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…To accurately assess longitudinal changes or the effect of potential therapeutic interventions on tau accumulation (either as a direct target or downstream measure) in vivo tau PET can be used. Several tau PET tracers became available over the years, of which [ 18 F]flortaucipir (previously known as [ 18 F]T-807 or [ 18 F]AV-1451) is most frequently used, and the only tau PET tracer (recently) approved by the FDA [1][2][3][4][5]. PET images can be acquired using static or dynamic scanning protocols.…”

Section: Introductionmentioning

confidence: 99%

Longitudinal tau PET using [¹⁸F]flortaucipir: Comparison of (semi)quantitative parameters

Visser

Tuncel

Ossenkoppele

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: Semi-quantitative PET measures can be affected by changes in blood flow, whereas quantitative measures are not. The aim of the study was to compare semi-quantitative(SUVr) and quantitative(R1, BPND) parameters of longitudinal tau PET scans with [18F]flortaucipir, with respect to changes in blood flow. Methods: Subjects with subjective cognitive decline(SCD; n=38) and Alzheimer′s disease(AD) patients(n=24) underwent baseline(BL) and 2-year follow-up(FU) dynamic [18F]flortaucipir PET scans. BPND and R1 were estimated using RPM and SUVr(80-100min) was calculated (cerebellar gray as reference). For each region-of-interest ((trans)entorhinal, limbic and neocortical) and parameter, %change was calculated. Regional SUVrs were compared to corresponding DVR (= BPND+1) using paired T-tests. Additionally, simulations were performed to model effects of flow changes on BPND and SUVr in different binding categories. Thereafter, %bias for SUVr with respect to underlying binding and flow were evaluated. Results: In SCD, there was a difference between %change in the (trans)entorhinal ROI (DVR 2.56% vs SUVr 1.85%) only. In AD, a difference was found in the limbic ROI (DVR 6.61% vs SUVr 7.52%) only. R1 changes were small(+0.7% in SCD and -1.6% in AD). Simulations illustrated with increasing flow a decreased %bias for SUVr in low binding conditions, whereas a slightly increased bias was observed in high binding conditions. Conclusion: SUVr provided an accurate estimate of specific binding for [18F]flortaucipir over a two-year follow-up. However, simulations showed that flow changes can affect [18F]flortaucipir SUVr, hence DVR/BPND should be preferred in more advanced disease stages and/or conditions that could induce significant flow changes like pharmacotherapeutic interventions.

show abstract

“…11 C]-Pittsburgh compound B([ 11 C]PIB), [ 18 F]florbetaben, [ 18 F]florbetapir, and [ 18 F]flutemetamol, of which the latter three are approved for use in AD diagnosis in the US and Europe(Jovalekic et al 2017;Uzuegbunam et al, 2020). The PET tracer [ 18 F]AV1451 has recently been approved in the US for tau imaging in AD(Jie et al, 2021).…”

mentioning

confidence: 99%

The role of neuroimaging in Parkinson’s disease

Bidesi

Andersen

Windhorst

et al. 2021

Journal of Neurochemistry

View full text Add to dashboard Cite

show abstract

Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease

Cited by 71 publications

References 60 publications

Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective

Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective

Longitudinal tau PET using [¹⁸F]flortaucipir: Comparison of (semi)quantitative parameters

The role of neuroimaging in Parkinson’s disease

Contact Info

Product

Resources

About

Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease

Cited by 71 publications

References 60 publications

Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective

Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective

Longitudinal tau PET using [18F]flortaucipir: Comparison of (semi)quantitative parameters

The role of neuroimaging in Parkinson’s disease

Contact Info

Product

Resources

About

Longitudinal tau PET using [¹⁸F]flortaucipir: Comparison of (semi)quantitative parameters